Download PDF
Klin Padiatr 2013; 225(S 01): S57-S61
DOI: 10.1055/s-0033-1337965
Zum 80. Geburtstag von Prof. Riehm
© Georg Thieme Verlag KG Stuttgart · New York

The Principle and Practice of Reinduction Therapy (in ALL): REPETITA IUVANT![*]

Prinzip und Praxis der Reinduktionstherapie (bei ALL): REPETITA IUVANT!**
G. Masera
1   Clinica Pediatrica dell’Università degli Studi di Milano-Bicocca – Ospedale San Gerardo – Fondazione MBBM, Monza (Italy)
,
V. Conter
1   Clinica Pediatrica dell’Università degli Studi di Milano-Bicocca – Ospedale San Gerardo – Fondazione MBBM, Monza (Italy)
,
P. S. Gaynon
2   Children’s Hospital Los Angeles, Los Angeles (USA)
› Author Affiliations
Further Information

Publication History

Publication Date:
22 May 2013 (online)

Also available at
    Permissions and Reprints

Key words

acute lymphoblastic ­leukemia (ALL) - Berlin-Frankfurt-Münster (BFM) group - delayed intensification - AIEOP - COG

Schlüsselwörter

akute lymphoblastische Leukämia (ALL) - Berlin-Frankfurt-Münster (BFM) Studiengruppe - Reinduktionstherapie - AIEOP - COG

* Repeating does good!


 

  • References

  • 1 Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727-1733
    PubMedGoogle Scholar
  • 2 Riehm H, Gadner H, Welte K. Die West-Berliner Studie zur Behandlung der akuten lymphoblastischen Leukämie des Kindes – Erfahrungsbericht nach 6 Jahren. Klin Pädiatr 1977; 189: 89-102
    PubMedGoogle Scholar
  • 3 Riehm H, Gadner H, Henze G et al. The Berlin childhood acute lymphoblastic leukemia therapy study, 1970–1976. Am J Pediatr Hematol Oncol 1980; 2: 299-306
    PubMedGoogle Scholar
  • 4 Henze G, Langermann H-J, Brämswig J et al. Ergebnisse der Studie BFM 76/79 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen (Results of study BFM 76/79 for treatment of acute lymphoblastic leukemia in childhood and adolescence). Klin Pädiatr 1981; 193: 145-154
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Riehm H, Gadner H, Henze G et al. Acute lymphoblastic leukemia: treatment results in three BFM studies (1970–1981). In: Murphy SB, Gilbert JR. (eds.). Leukemia Research: Advances in Cell Biology and Treatment. Elsevier Science; Amsterdam: 1983: 251-263
    Google Scholar
  • 6 Henze G, Langermann HJ, Ritter J et al. Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia: A Report From the BFM Study Group. Haematol Blood Transfus 1981; 26: 87-93
    PubMedGoogle Scholar
  • 7 Norton L, Simon R, Brereton HD et al. Predicting the course of Gompertzian growth. Nature 1976; 264: 542-545
    CrossrefPubMedGoogle Scholar
  • 8 Broder LE, Carbone PP. Pharmacokinetic considerations in the design of optimal chemotherapeutic regimens for the treatment of breast carcinoma: a conceptual approach. Med Pediatr Oncol 1976; 2: 11-27
    CrossrefPubMedGoogle Scholar
  • 9 Camitta BM, Pinkel D, Thatcher LG et al. Failure of early intensive chemotherapy to improve prognosis in childhood acute lymphocytic leukemia. Med Pediatr Oncol 1980; 8: 383-389
    CrossrefPubMedGoogle Scholar
  • 10 Gaynon PS, Bleyer WA, Steinherz PG et al. Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. report of Children’s Cancer Study Group study CCG-193p. Am J Pediatr Hematol Oncol 1988; 10: 42-50
    CrossrefPubMedGoogle Scholar
  • 11 Gaynon PS, Steinherz PG, Bleyer WA et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106. J Clin Oncol 1993; 11: 2234-2242
    PubMedGoogle Scholar
  • 12 Steinherz PG, Gaynon PS, Breneman JC et al. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children’s Cancer Group. Cancer 1998; 82: 600-612
    CrossrefPubMedGoogle Scholar
  • 13 Tubergen D, Gilchrist G, O’Brien A et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features. J Clin Oncol 1993; 11: 527-537
    PubMedGoogle Scholar
  • 14 Tubergen DG, Gilchrist GS, O’Brien RT et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report. Journal of Clinical Oncology 1993; 11: 520-526
    PubMedGoogle Scholar
  • 15 Nachman J, Sather HN, Gaynon PS et al. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children’s Cancer Group. J Clin Oncol 1997; 15: 2222-2230
    PubMedGoogle Scholar
  • 16 Nachman JB, Sather HN, Sensel MG et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998; 338: 1663-1671
    CrossrefPubMedGoogle Scholar
  • 17 Nachman J, Sather HN, Cherlow JM et al. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children’s Cancer Group. Journal of Clinical Oncology 1998; 16: 920-930
    PubMedGoogle Scholar
  • 18 Matloub Y, Bostrom BC, Hunger SP et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood 2011; 118: 243-251
    CrossrefPubMedGoogle Scholar
  • 19 Larsen EC, Salzer WL, Devidas M et al. Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children’s Oncology Group Study AALL0232. J Clin Oncol 2011; 29 (suppl; abstr 3)
    PubMedGoogle Scholar
  • 20 Winick NJ, Salzer WL, Devidas M et al. Dexamethasone (DEX) versus prednisone (PRED) during induction for children with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children’s Oncology Group Study AALL0232. J Clin Oncol 2011; 29 (suppl; abstr 9504)
    PubMedGoogle Scholar
  • 21 Seibel NL, Steinherz PG, Sather HN et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood 2008; 111: 2548-2555
    CrossrefPubMedGoogle Scholar
  • 22 Mattano Jr LA, Devidas M, Nachman JB et al. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol 2012; 13: 906-915
    CrossrefPubMedGoogle Scholar
  • 23 Vora AJ, Goulden N, Mitchell CD et al. A Randomised Trial Investigating Treatment Intensification for Children and Young Adults with Minimal Residual Disease Defined High Risk Acute Lymphoblastic Leukaema. Blood 2012; 120 Abstract 136
    PubMedGoogle Scholar
  • 24 Hunger SP, Lu X, Devidas M et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol 2012; 30: 1663-1669
    CrossrefPubMedGoogle Scholar
  • 25 Gaynon PS, Angiolillo AL, Carroll WL et al. Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children’s Oncology Group Report. Leukemia 2010; 24: 285-297
    PubMedGoogle Scholar
  • 26 Vecchi V, Aricò M, Basso G et al. Risk-directed therapy for childhood acute lymphoblastic leukemia. Results of the Associazione Italiana Ematologia Oncologia Pediatrica ’82 studies. Cancer 1993; 72: 2517-2524
    CrossrefPubMedGoogle Scholar
  • 27 Arico M, Valsecchi MG, Rizzari C et al. Long-term results of the AIEOP-ALL-95 trial for childhood acute lymphoblastic leukemia: Insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster-based chemotherapy. J Clin Oncol 2008; 26: 283-289
    CrossrefPubMedGoogle Scholar
  • 28 Conter V, Arico M, Valsecchi MG et al. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Haematologica 1998; 83: 791-799
    PubMedGoogle Scholar
  • 29 Rizzari C, Valsecchi MG, Aricò M et al. for the Associazione Italiana Ematologia Oncologia Pediatrica . Effect of Protracted High-Dose L-Asparaginase Given as a Second Exposure in a Berlin-Frankfurt-Münster-Based Treatment: Results of the Randomized 9102 Intermediate-Risk Childhood Acute Lymphoblastic Leukemia Study – A Report From the Associazione Italiana Ematologia Oncologia Pediatrica. J Clin Oncol 2001; 19: 1297-1303
    PubMedGoogle Scholar
  • 30 Schrappe M, Reiter A, Ludwig WD et al. for the German-Austrian-Swiss ALL-BFM Study Group et al . Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood 2000; 95: 3310-3322
    PubMedGoogle Scholar
  • 31 Millot F, Suciu S, Philippe N et al. for the Children’s Leukemia Cooperative Group of the European Organization for Research and Treatment of Cancer . Value of High-Dose Cytarabine During Interval Therapy of a Berlin-Frankfurt-Munster-Based Protocol in Increased-Risk Children With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: Results of the European Organization for Research and Treatment of Cancer 58881 Randomized Phase III Trial. J Clin Oncol 2001; 19: 1935-1942
    PubMedGoogle Scholar
  • 32 Kamps WA, Bökkerink JPM, Hakvoort-Cammel FGAJ et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8(1991–1996). Leukemia 2002; 16: 1099
    PubMedGoogle Scholar
  • 33 Pession A, Valsecchi MG, Masera G et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23: 7161-7167
    CrossrefPubMedGoogle Scholar
  • 34 Balduzzi A, Valsecchi MG, Uderzo C et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 2005; 366: 635-642
    CrossrefPubMedGoogle Scholar
  • 35 Conter V, Valsecchi MG, Silvestri D et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet 2007; 369: 123-131
    CrossrefPubMedGoogle Scholar
  • 36 Biondi A, Schrappe M, De Lorenzo P et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol 2012; 13: 936-945
    CrossrefPubMedGoogle Scholar
  • 37 Stary J, Zimmermann M, Campbell M et al. Results of the Randomized I-BFM-SG Trial “Acute Lymphoblastic Leukemia Intercontinental-BFM 2002” in 5060 Children Diagnosed in 15 Countries on 3 Continents. Blood (ASH Annual Meeting Abstracts) 2011; 118: 872
    PubMedGoogle Scholar
  • 38 Hertzberg L, Vendramini E, Ganmore I et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010; 115: 1006-1017
    CrossrefPubMedGoogle Scholar
  • 39 Flohr T, Schrauder A, Cazzaniga G et al. International BFM Study Group . (I-BFM-SG). Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771-782
    CrossrefPubMedGoogle Scholar
  • 40 Bercovich D, Ganmore I, Scott LM et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down’s syndrome. Lancet 2008; 372: 1484-1492
    CrossrefPubMedGoogle Scholar
  • 41 Van der Velden VH, Corral L, Valsecchi MG et al. Interfant-99 Study Group . Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 2009; 23: 1073-1079
    PubMedGoogle Scholar
  • 42 Conter V, Bartram CR, Valsecchi MG et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3 184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 3206-3214
    CrossrefPubMedGoogle Scholar
  • 43 Schrappe M, Valsecchi MG, Bartram CR et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 2011; 118: 2077-2084
    CrossrefPubMedGoogle Scholar